Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 1,304 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Pediatric Clear all
Recruiting Not applicable Interventional

Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma

NCT07506239
View directory record Official record
Conditions
Low-grade Glioma, Recurrent Low Grade Glioma, Low Grade Glioma of Brain, Pediatric Cancer
Interventions
Laser Interstitial Thermal Therapy (LITT), Magnetic resonance imaging (MRI), Questionnaires
Device · Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 29, 2026, 5:13 AM EDT
Recruiting Phase 1Phase 2 Interventional

ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma

NCT04634357
View directory record Official record
Conditions
Hepatoblastoma, Hepatocellular Carcinoma (HCC), Liver Neoplasms, Metastatic Liver Cancer, Liver Cancer, HEMNOS
Interventions
ET140203 T Cells
Drug
Lead sponsor
Eureka Therapeutics Inc.
Industry
Eligibility
1 Year to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 29, 2026, 5:13 AM EDT
Completed Not applicable Interventional Results available

Mobile Health Fitness Program for Adolescent and Young Adult Childhood Cancer Survivors

NCT02688192
View directory record Official record
Conditions
Survivorship, Fatigue
Interventions
Exercise Intervention, Internet-Based Intervention, Monitoring Device, Quality-of-Life Assessment
Behavioral · Device · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
13 Years to 25 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Hackensack, New Jersey • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 29, 2026, 5:13 AM EDT
Completed Not applicable Interventional Results available

PET/MRI and PET/CT in Diagnosing Younger Patients With Cancer

NCT02287636
View directory record Official record
Conditions
Childhood Cancer
Interventions
fludeoxyglucose F 18, positron emission tomography, computed tomography, magnetic resonance imaging
Radiation · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 29, 2026, 5:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessing Neurophysiological and Cognitive Function in School Children

NCT06209528
View directory record Official record
Conditions
Pediatric ALL
Interventions
Not listed
Lead sponsor
Life University
Other
Eligibility
5 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Chippewa Falls, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 29, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Statin Therapy in Young Adult Survivors of Childhood Cancer

NCT01733953
View directory record Official record
Conditions
Cardiovascular Disease, Childhood ALL, Childhood NHL
Interventions
Atorvastatin, Sugar Pill (Placebo)
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 39 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 29, 2026, 5:13 AM EDT
Completed Phase 1 Interventional Results available

EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

NCT02601937
View directory record Official record
Conditions
Rhabdoid Tumors, INI1-negative Tumors, Synovial Sarcoma, Malignant Rhabdoid Tumor of Ovary
Interventions
Tazemetostat
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 29, 2026, 5:13 AM EDT
Recruiting No phase listed Observational

Evaluating the Relationship Between Skin Color and Pulse Oximeter Accuracy in Children

NCT06529575
View directory record Official record
Conditions
Pediatric ALL, Cardiac Defect
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
4 Weeks to 18 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
New York, New York • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 29, 2026, 5:13 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Multicenter HomeVENT: Home Values and Experiences Navigation Track

NCT06102330
View directory record Official record
Conditions
Pediatric ALL, Respiratory Insufficiency, Communication
Interventions
HomeVENT decision support tool
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
4
States / cities
Tampa, Florida • New Orleans, Louisiana • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 29, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

A Study in Adults With Untreated Acute Lymphoblastic Leukemia

NCT00136435
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
prednisone, doxorubicin, vincristine, methotrexate, asparaginase, dexamethasone, cranial radiation, leucovorin, cytarabine, hydrocortisone, 6-mercaptopurine (6-MP), e. coli L-asparaginase
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 29, 2026, 5:13 AM EDT
Completed No phase listed Observational

Pediatric EEG Monitoring

NCT04664608
View directory record Official record
Conditions
Pediatric ALL, Epilepsy
Interventions
wearable EEG sensor
Device
Lead sponsor
Northwestern University
Other
Eligibility
1 Day to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 29, 2026, 5:13 AM EDT
Completed Phase 1 Interventional

Clofarabine in Adult Patients With Advanced Solid Tumors

NCT00125840
View directory record Official record
Conditions
Solid Tumors, Leukemia, Lymphocytic, Acute, Pediatric, Leukemia, Lymphocytic, Acute, Adult, Leukemia, Myelocytic, Acute, Pediatric, Leukemia, Myelocytic, Acute, Adult, Myelodysplastic Syndromes, Adult
Interventions
clofarabine (IV formulation)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
2
States / cities
Dallas, Texas • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Oct 29, 2026, 5:13 AM EDT
Completed Not applicable Interventional Results available

Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors

NCT04469569
View directory record Official record
Conditions
Papillomavirus Vaccines
Interventions
HPV-PROTECT
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
9 Years and older
Enrollment
8,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • Atlanta, Georgia • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 29, 2026, 5:13 AM EDT
Withdrawn Phase 1 Interventional

Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer

NCT02800889
View directory record Official record
Conditions
Lymphoma, Solid Tumor (Excluding CNS)
Interventions
Pixantrone
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
6 Months to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 29, 2026, 5:13 AM EDT
Completed No phase listed Observational

Pilot Test for a Newly Developed Nutrition Screening Method: Pediatric Subjective Global Assessment

NCT00665691
View directory record Official record
Conditions
Compare Two Nutrition Screening Tools
Interventions
Nutritional Screening Tools
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 16 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 29, 2026, 5:13 AM EDT
Recruiting Phase 2 Interventional

Study of Olutasidenib and Temozolomide in HGG

NCT06161974
View directory record Official record
Conditions
High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma, WHO Grade IV Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Thalamus Tumor, Spinal Tumor, IDH1 Mutation, IDH1 R132, IDH1 R132C, IDH1 R132H, IDH1 R132S, IDH1 R132G, IDH1 R132L, Oligodendroglioma
Interventions
Olutasidenib + TMZ
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
12 Years to 39 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
11
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 29, 2026, 5:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants

NCT04771390
View directory record Official record
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
Selitrectinib (BAY2731954) Adult tablet, Selitrectinib (BAY2731954) Pediatric tablet, Selitrectinib (BAY2731954) Oral solution, Selitrectinib (BAY2731954) Oral suspension
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 29, 2026, 5:13 AM EDT
Recruiting Not applicable Interventional

Development and Evaluation of a Screening Approach for Sexual Dysfunction in AYA Patients With and Surviving Childhood Cancer

NCT05524610
View directory record Official record
Conditions
Pediatric Cancer, Survivorship
Interventions
Sexual Function Screening Approach
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
15 Years to 24 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 29, 2026, 5:13 AM EDT
Recruiting Not applicable Interventional

A Study of Time-Restricted Eating in Childhood Cancer Survivors

NCT07009288
View directory record Official record
Conditions
Childhood Cancer Survivors
Interventions
Children's Oncology Group Heart Health Link, Monthly weights, Fasting, Calls, Participant Questionnaires, Dried blood spot
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
4
States / cities
New York, New York • Memphis, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 29, 2026, 5:13 AM EDT
Completed No phase listed Observational

Concurrent School Attendance And Cancer Therapy: The Experiences of 6-12 Year Old Pediatric Oncology Patients

NCT01383473
View directory record Official record
Conditions
Leukemia, Lymphoma, Solid Tumor
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 27, 2015 · Synced Oct 29, 2026, 5:13 AM EDT
Active, not recruiting Phase 2 Interventional Results available

MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

NCT03962543
View directory record Official record
Conditions
Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1)
Interventions
Mirdametinib (PD-0325901) oral capsule or dispersible tablet
Drug
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
2 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 29, 2026, 5:13 AM EDT
Completed Not applicable Interventional Results available

Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer

NCT03435380
View directory record Official record
Conditions
Breast Neoplasms, Early Detection of Cancer
Interventions
Patient activation, Primary care physician activation, Control
Behavioral
Lead sponsor
Duke University
Other
Eligibility
25 Years and older · Female only
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
New York, New York • Durham, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 29, 2026, 5:13 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

NCT03834961
View directory record Official record
Conditions
Central Nervous System Neoplasm, Infantile Fibrosarcoma, Recurrent Acute Leukemia, Refractory Acute Leukemia, Solid Neoplasm
Interventions
Larotrectinib Sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
78
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 29, 2026, 5:13 AM EDT
Active, not recruiting Phase 1 Interventional

A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia

NCT03330691
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Patient-derived CD19- and CD22 specific CAR
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
Up to 30 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2035
U.S. locations
4
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 29, 2026, 5:13 AM EDT